Glioblastoma Clinical Trials Update and Drugs Analysis: EMA, PDMA, FDA Approvals, Medication, Therapies, NDA, IND, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight

(Albany, USA) "Glioblastoma Pipeline Insight 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.

As per DelveInsight's assessment, globally, Glioblastoma pipeline constitutes 190+ key companies continuously working towards developing 200+ Glioblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyses DelveInsight.

Request for Sample Report, here @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Glioblastoma Pipeline Report:
• Glioblastoma Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years.
• Glioblastoma companies working in the treatment market are Candel Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc.,GlaxoSmithKline, NuvOx Pharma, Biohaven Pharmaceuticals, Vigeo Therapeutics, TVAX Biomedical, Denovo Biopharma, Accendatech, Apollomics, IN8bio, Genenta Science, Sapience Therapeutics, VBI Vaccines, Karyopharm Therapeutics, Novartis, Grupo Español de Investigación en Neurooncología, Plus Therapeutics, Turning Point Therapeutics, Neonc Technologies, and others, are developing therapies for the Glioblastoma treatment
• Emerging Glioblastoma therapies in the different phases of clinical trials are Enzastaurin, Marizomib, Nivolumab, MBM-02, VT1021, Temozolomide, ADI-PEG20, ONC201 and others are expected to have a significant impact on the Glioblastoma market in the coming years.
• In December 2024, Kazia Therapeutics was informed by the FDA that accelerated approval for its brain cancer drug, paxalisib, is unlikely. The FDA stated that the Phase II/III GBM-AGILE study's overall survival data, showing a 3.8-month improvement in glioblastoma patients, does not meet the criteria for accelerated approval.
• On October 15, 2024, the FDA granted Fast Track designation to LP-184, a small-molecule alkylating agent developed by Lantern Pharma for the treatment of glioblastoma (GBM). LP-184 induces tumor cell death through DNA damage and is currently in a Phase 1a trial assessing its safety and tolerability in patients with various solid tumors, including GBM. The Fast Track status aims to accelerate the development and review of LP-184, particularly given the limited treatment options for aggressive brain cancers like GBM.

Glioblastoma Overview
Glioblastoma (GBM) is the most aggressive and common malignant primary brain tumor in adults, classified as a Grade IV glioma by the World Health Organization (WHO). It originates from astrocytes, the star-shaped glial cells in the brain, and is characterized by rapid growth, extensive infiltration into surrounding brain tissue, and resistance to standard therapies. GBM is highly heterogeneous, with a complex genetic and molecular landscape, including alterations in EGFR, PTEN, and TP53.

Symptoms of glioblastoma depend on tumor location and may include headaches, seizures, cognitive impairment, personality changes, and neurological deficits. Diagnosis is typically confirmed through magnetic resonance imaging (MRI) and biopsy. Standard treatment includes maximal safe surgical resection, followed by radiation therapy and chemotherapy with temozolomide. Despite aggressive treatment, GBM has a poor prognosis, with a median survival of approximately 12-15 months.

Recent advancements in research focus on targeted therapies, immunotherapy, tumor-treating fields (TTF), and gene therapy to improve patient outcomes. However, the blood-brain barrier and tumor heterogeneity pose significant challenges in drug delivery and treatment efficacy. Due to its aggressive nature and high recurrence rate, glioblastoma remains a major area of investigation in neuro-oncology.

Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:
• Enzastaurin: Denovo BioPharma
• Marizomib: Bristol-Myers Squibb
• VT1021: Vigeo Therapeutics
• ONC201: Chimerix, Inc.
• And others.

Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Know more about Glioblastoma pipeline Analysis @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Molecule Type
Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Glioblastoma Pipeline Therapeutics Assessment
• Glioblastoma Assessment by Product Type
• Glioblastoma By Stage and Product Type
• Glioblastoma Assessment by Route of Administration
• Glioblastoma By Stage and Route of Administration
• Glioblastoma Assessment by Molecule Type
• Glioblastoma by Stage and Molecule Type

DelveInsight's Glioblastoma Pipeline Report covers around 190+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies at: https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Glioblastoma Therapeutics Market include:
Key Glioblastoma companies developing therapies are Candel Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc.,GlaxoSmithKline, NuvOx Pharma, Biohaven Pharmaceuticals, Vigeo Therapeutics, TVAX Biomedical, Denovo Biopharma, Accendatech, Apollomics, IN8bio, Genenta Science, Sapience Therapeutics, VBI Vaccines, Karyopharm Therapeutics, Novartis, Grupo Español de Investigación en Neurooncología, Plus Therapeutics, Turning Point Therapeutics, Neonc Technologies, and others.

Glioblastoma Pipeline Analysis:
The Glioblastoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
• Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

Download Sample PDF Report to know more about Glioblastoma drugs and therapies- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Glioblastoma Pipeline Market Drivers
The glioblastoma pipeline market, a highly aggressive brain tumor, is driven by several factors. Firstly, the high unmet medical need and limited treatment options for glioblastoma create a strong demand for innovative therapies. The increasing incidence of glioblastoma cases globally contributes to the market growth. Additionally, advancements in technology and understanding of the molecular basis of the disease have led to the discovery of potential targets for therapeutic intervention. Collaboration between pharmaceutical companies, academic institutions, and research organizations has facilitated the development of novel treatment approaches. Lastly, regulatory incentives and fast-track designations by regulatory authorities have expedited the development and approval process for glioblastoma therapies.

Glioblastoma Pipeline Market Barriers
The glioblastoma pipeline market faces several barriers that impact its development and growth. Firstly, the complexity and heterogeneity of glioblastoma tumors pose significant challenges in identifying effective therapeutic targets and developing targeted therapies. The blood-brain barrier also limits the delivery of drugs to the tumor site, reducing their effectiveness. Glioblastoma's aggressive nature and rapid progression make it difficult to conduct clinical trials and evaluate the long-term efficacy of potential treatments. Moreover, the high cost of research and development, coupled with the uncertain reimbursement landscape, may deter pharmaceutical companies from investing in glioblastoma therapies. Regulatory requirements and stringent approval processes also add to the challenges in bringing new treatments to market. Lastly, limited patient enrollment in clinical trials and the scarcity of reliable biomarkers further complicate the development of innovative therapies for glioblastoma.

Scope of Glioblastoma Pipeline Drug Insight
• Coverage: Global
• Key Glioblastoma Companies: Candel Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc.,GlaxoSmithKline, NuvOx Pharma, Biohaven Pharmaceuticals, Vigeo Therapeutics, TVAX Biomedical, Denovo Biopharma, Accendatech, Apollomics, IN8bio, Genenta Science, Sapience Therapeutics, VBI Vaccines, Karyopharm Therapeutics, Novartis, Grupo Español de Investigación en Neurooncología, Plus Therapeutics, Turning Point Therapeutics, Neonc Technologies, and others.
• Key Glioblastoma Therapies: Enzastaurin, Marizomib, VT1021, ONC201 and others.
• Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
• Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers

Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Glioblastoma Report Introduction
2. Glioblastoma Executive Summary
3. Glioblastoma Overview
4. Glioblastoma- Analytical Perspective In-depth Commercial Assessment
5. Glioblastoma Pipeline Therapeutics
6. Glioblastoma Late Stage Products (Phase II/III)
7. Glioblastoma Mid Stage Products (Phase II)
8. Glioblastoma Early Stage Products (Phase I)
9. Glioblastoma Preclinical Stage Products
10. Glioblastoma Therapeutics Assessment
11. Glioblastoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Glioblastoma Key Companies
14. Glioblastoma Key Products
15. Glioblastoma Unmet Needs
16 . Glioblastoma Market Drivers and Barriers
17. Glioblastoma Future Perspectives and Conclusion
18. Glioblastoma Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market-forecast
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Xerostomia Market: https://www.delveinsight.com/whitepaper-newsletter/xerostomia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Pharma Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Surgical Site Infections Market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Febrile Neutropenia Market: https://www.delveinsight.com/report-store/febrile-neutropenia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
Case study: https://www.delveinsight.com/case-study/go-to-market-strategy

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.